NCT07300943 2026-03-13
Study in Advanced Solid Tumor Patients
Callio Therapeutics
Phase 1/2 Recruiting
Clinical Trials
93 trialsNCT06057922 2026-03-12
A Study YL201 in Patients With Selected Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Active not recruiting
NCT06685068 2026-03-03
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT06833008 2026-02-27
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Phase 1/2 Recruiting
NCT06911827 2026-02-25
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT05518045 2026-02-04
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
LaNova Medicines Limited
Phase 1/2 Active not recruiting
NCT05443126 2026-02-03
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
Ellipses Pharma
Phase 1/2 Recruiting
NCT05756907 2026-02-03
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Sonnet BioTherapeutics
Phase 1/2 Terminated
NCT05744427 2026-02-02
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2 Active not recruiting
NCT05163041 2026-01-15
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
BicycleTx Limited
Phase 1/2 Active not recruiting
NCT07339748 2026-01-15
A Clinical Study of ZL-85FA Tablets
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2 Not yet recruiting
NCT04284488 2026-01-08
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT05584800 2026-01-05
Study of ZGGS18 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT06938880 2026-01-05
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT07124117 2026-01-05
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
OBI Pharma, Inc
Phase 1/2 Recruiting
NCT07298772 2025-12-23
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06825494 2025-12-18
Clinical Studies for the Treatment of Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT07256782 2025-12-01
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT07083323 2025-11-25
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT06345482 2025-11-20
A Study of MHB039A for Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Active not recruiting
NCT06373406 2025-11-19
A Study of MHB036C for Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Active not recruiting
NCT05434234 2025-11-10
A Study of YL201 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT06635785 2025-11-10
BiPAVE-001
OncoC4, Inc.
Phase 1/2 Recruiting
NCT04497116 2025-10-21
TRESR
Repare Therapeutics
Phase 1/2 Completed
NCT06260774 2025-10-02
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
TransCode Therapeutics
Phase 1/2 Active not recruiting
NCT05821777 2025-09-25
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
Centessa Pharmaceuticals plc
Phase 1/2 Terminated
NCT06682780 2025-09-25
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT05161390 2025-09-12
Study of LM-302 in Patients With Advance Solid Tumors
LaNova Medicines Limited
Phase 1/2 Completed
NCT05199753 2025-09-12
Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Completed
NCT06226766 2025-09-10
JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2 Terminated
NCT06187402 2025-09-09
A Study of LM-24C5 For Advanced Solid Tumors
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT05684965 2025-09-08
XTX301 in Patients With Advanced Solid Tumors
Xilio Development, Inc.
Phase 1/2 Recruiting
NCT07157956 2025-09-05
CVL006-T1002
Convalife (Shanghai) Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07142837 2025-08-27
Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Not yet recruiting
NCT05109442 2025-08-20
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT05761223 2025-08-17
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
1ST Biotherapeutics, Inc.
Phase 1/2 Recruiting
NCT06953323 2025-08-13
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06480240 2025-08-08
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
OBI Pharma, Inc
Phase 1/2 Active not recruiting
NCT05978102 2025-07-23
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 1/2 Recruiting
NCT04259450 2025-07-17
Study to Assess AFM24 in Advanced Solid Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT06277219 2025-07-08
LIGHTSPEED-1
Latticon Antibody Therapeutics, Inc
Phase 1/2 Recruiting
NCT04896697 2025-05-29
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Xilio Development, Inc.
Phase 1/2 Recruiting
NCT04322006 2025-05-22
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
Phase 1/2 Active not recruiting
NCT05170958 2025-05-22
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT04914286 2025-05-14
A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2 Completed
NCT06970132 2025-05-14
Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation
Shouyao Holdings (Beijing) Co. LTD
Phase 1/2 Not yet recruiting
NCT05263960 2025-05-04
A Study of CM350 in Patients With Advanced Solid Tumors
Keymed Biosciences Co.Ltd
Phase 1/2 Recruiting
NCT05038150 2025-04-30
Study of SGN1 in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT05103345 2025-04-30
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT06431243 2025-04-10
A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2 Recruiting